skip to Main Content

Selective Dismutase Mimetic/SBRT Improves OS in Locally Advanced Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The addition of avasopasem manganese (GC4419) to stereotactic body radiation therapy (SBRT) led to a significant improvement in overall survival (OS) and favorable progression-free survival (PFS) versus SBRT plus placebo in patients with locally advanced pancreatic cancer, according to interim data from a phase 1/2 trial (NCT03340974) that were presented virtually during the 2020 ASTRO Annual Meeting.

In the intent-to-treat cohort (n = 19), with a median follow-up of at least 1 year, the median OS had not yet been reached with avasopasem manganese/SBRT (n = 11) compared with 40.4 weeks in the SBRT/placebo arm (n = 8; HR, 0.30; P = .046). Read more . . . 


Back To Top